Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-4513

293T-CDH1-Cell-Line

Home » 293T-CDH1-Cell-Line

Background of 293T-CDH1-Cell-Line

CDH1 (Cadherin 1) is a Protein Coding gene, it is encodes a classical cadherin of the cadherin superfamily. E-Cadherin protein is necessary for physiological signaling pathways, such as cell proliferation, maintenance of cell adhesion, cell polarity and epithelial-mesenchymal transition. it dysregulation leads to tumor proliferation, invasion, migration and metastases. Germline mutation in CDH1 (E-cadherin) tumor suppressor gene is associated with hereditary diffuse gastric cancer (HDGC) and lobular breast cancers (LBC). Diseases associated with CDH1 include Diffuse Gastric And Lobular Breast Cancer Syndrome and Blepharocheilodontic Syndrome 1.

Specifications

Catalog Number:
KC-4513
Cell Line Name:
293T-CDH1-Cell-Line
Clone Number
Host Cell Line:
293T
Description:
Stable HEK293T clone expressing exogenous human CDH1 gene
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% DMEM + 20% FBS + 10% DMSO
Propagation Medium:
DMEM + 10% FBS + 1μg/mL Puromycin
Selection Marker:
Puromycin
Morphology:
Epithelial
Subculture:
Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 30 hours
Mycoplasma Status:
Negative
In Vivo Validation:
NA

Cell Line Generation

293T-CDH1 cell line was generated using a lentiviral vector expressing the human CDH1 sequence.

Characterization

Figure 1: haracterization of human CDH1 overexpression in the 293T CDH1 stable clone using FACS.

Figure 2: Characterization of human CDH1 in the 293T CDH1 stable clone using PCR sequencing.

Cell Resuscitation

  1. Prewarm culture medium (DMEM supplemented with 10% FBS and 1μg/mL puromycin)in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage

References

  1. Wang, J., Xiu, J., Battaglin, F. et al. Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer. npj Precis. Onc. 8, 214 (2024).
  2. Shenoy S. CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management. Cancer Manag Res. 2019 Dec 13;11:10477-10486. doi: 10.2147/CMAR.S208818. PMID: 31853199; PMCID: PMC6916690.
  3. Adib, E., El Zarif, T., Nassar, A.H. et al. CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. Br J Cancer 126, 797–803 (2022).